Increased production of interleukin-1 and tumor necrosis factor by human monocytes treated in vitro with cisplatin or other biological response modifiers.
Supernatants collected from cisplatin, lipopolysaccharide (LPS), muramyl dipeptide (MDP) or interferon-gamma (IFN-gamma) treated human monocytes enhance the thymocyte proliferation by a submitogenic concentration of concanavalin A. Also supernatants collected from cisplatin or IFN-gamma treated monocytes demonstrated enhanced cytotoxicity against actinomycin-D treated L 929 cells, suggesting that cisplatin or rIFN-gamma treated monocytes release tumor necrosis factor (TNF) into the culture medium. The supernatant collected from untreated monocytes showed only little IL-1 and TNF activity.
Sodhi
A
A
School of Biotechnology, Banaras Hindu University, Varanasi, India.
Pai
K
K
D002945:Cisplatin / Q000494:pharmacology*; D003470:Culture Media; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology*; D007375:Interleukin-1 / Q000096:biosynthesis*; D009000:Monocytes / Q000187:drug effects* / Q000276:immunology*; D016260:Monocytes, Activated Killer / Q000276:immunology; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
D003470:Culture Media; D007155:Immunologic Factors; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D002945:Cisplatin